Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Status:
Recruiting
Trial end date:
2023-10-16
Target enrollment:
Participant gender:
Summary
This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment
clinical responses to lenalidomide in patients with near complete remission (nCR), or
complete remission (CR) leading to a significant improvement in progression-free
survival.This main objective of this study is to compare the 2-year progression free survival
of patients with multiple myeloma in CR or nCR, treated with lenalidomide plus an allogeneic
myeloma vaccine in combination with lenalidomide (with or without Prevnar vaccine) or versus
placebo in combination with lenalidomide (control arm).
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins